Used in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dysregulated dopamine signaling. By inhibiting PDE10A, it modulates cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in striatal neurons, which play key roles in motor control, cognition, and behavior. Its ability to cross the blood-brain barrier enhances its utility in neuropharmacological studies. It serves as a valuable tool compound for validating PDE10A as a therapeutic target and for exploring signaling pathways in basal ganglia-related diseases.